With growing evidence that RIPK1 plays a critical role in modulating microglia activity in neurodegeneration, there is an increasing number of RIPK1 inhibitors being investigated in human clinical studies for treating neurodegenerative diseases, such as ALS and AD [83]. This evidence concerns the gene RIPK1 and Alzheimer disease.